Protalix BioTherapeutics (PLX) EBITDA Margin (QoQ) (2010 - 2026)
Powered by 
Analysis
Protalix BioTherapeutics (PLX) EBITDA Margin (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Protalix BioTherapeutics | 218.36 Mn | 177.71 Mn | 12.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,971.00 |
| Mar 31, 2026 | 11,067.00 |
| Dec 31, 2025 | -6,084.00 |
| Sep 30, 2025 | 579.00 |
| Jun 30, 2025 | 4,580.00 |
| Mar 31, 2025 | -7,897.00 |
| Dec 31, 2024 | 1,735.00 |
| Sep 30, 2024 | 3,970.00 |
| Jun 30, 2024 | 11,392.00 |
| Mar 31, 2024 | -7,601.00 |
| Dec 31, 2023 | -3,531.00 |
| Sep 30, 2023 | -7,646.00 |
| Jun 30, 2023 | 8,387.00 |
| Mar 31, 2023 | 331.00 |
| Dec 31, 2022 | -692.00 |
| Sep 30, 2022 | 4,108.00 |
| Jun 30, 2022 | -5,148.00 |
| Mar 31, 2022 | 5,512.00 |
| Dec 31, 2021 | -5,111.00 |
| Sep 30, 2021 | 12,698.00 |